Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Endostar Combined With Toripalimab for Resectable Melanoma
NCT05907512Phase 2Unknown
- Sponsor
- Fudan University
- Start
- Apr 2020
- Primary completion
- Aug 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of endostar, toripalimab in cutaneous melanoma (CM), sponsored by Fudan University. Status: unknown.
02
Drugs
endostartoripalimab
03
Conditions
cutaneous melanoma (CM)
Beyond the preview
Go deeper on NCT05907512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05907512.